Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06118112
Other study ID # LONGCOVID EXPERIENCE
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 18, 2023
Est. completion date December 30, 2024

Study information

Verified date November 2023
Source Corporacion Parc Tauli
Contact Pilar Peña, MD
Phone +34937231010
Email ppena@tauli.cat
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: One in ten people infected with COVID-19 presents persistent COVID, which consists of the presence of symptoms three months after the acute manifestations of COVID-19 and their persistence for at least two months, without being explained by an alternative diagnosis. The characteristics and clinical approach to persistent COVID syndrome are fairly well known, but not what the experience of people with persistent COVID is in relation to their daily life, their work life, and their experience with the healthcare received. Objective: to understand the experience of patients with persistent COVID in relation to the disease, the health care received and re-entry into the world of work Methods: Qualitative, descriptive, phenomenological study, based on individual interviews. The study protocol will be registered in Clinicaltrials.gov. People with persistent COVID treated at the Parc Taulí Hospital will be included. Sampling will be by convenience, purposive and snowball and the sample size will be determined by data saturation. Semi-structured individual or group interviews will be conducted and the data will be analyzed following a reflective thematic analysis (Brawn and Clarke). The preliminary report will be triangulated with some participants and with the results obtained from a scoping review carried out by the research team.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date December 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - women and men diagnosed with persistent COVID between March '20 to the present according to WHO criteria (persistent symptoms three months after the acute manifestations of COVID-19 and lasting at least two months and cannot be explained by an alternative diagnosis). - treated at the Parc TaulĂ­ Hospital - from 18 to 65 years Exclusion Criteria: -people who do not understand or can communicate in Catalan or Spanish.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Spain Corporació Sanitària Parc Taulí Sabadell Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Corporacion Parc Tauli Universitat Autonoma de Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Experience of the disease How is living with LongCOVID. Assessed through semi-structured interviews. Up to three years
Primary Experience with healthcare received How is the experience of patients with the healthcare received for their condition. Assessed through semi-structured interviews. Up to three years
Primary Experience with return to work What were the barriers and facilitators for returning to work after the disease. Assessed through semi-structures interviews. Up to three years
See also
  Status Clinical Trial Phase
Recruiting NCT05926505 - Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome Phase 2/Phase 3
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Completed NCT05552612 - Health-related Quality of Life and Long COVID
Completed NCT05531019 - COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A N/A
Not yet recruiting NCT04949386 - Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. Phase 2
Completed NCT05185674 - Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
Active, not recruiting NCT05965739 - RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms N/A
Active, not recruiting NCT05965752 - RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms N/A
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT05606211 - Pain in Long COVID-19: The Role of Sleep
Active, not recruiting NCT05713266 - Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
Completed NCT05601180 - Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID. N/A
Completed NCT05679505 - Vagus Nerve Stimulation for Post-COVID Syndrome N/A
Not yet recruiting NCT06045338 - Mind Body Intervention for Long COVID N/A
Recruiting NCT06091358 - Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation. N/A
Recruiting NCT05566392 - Longterm Influence of Pediatric Long COVID Syndrome
Recruiting NCT05855369 - Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss Phase 2/Phase 3
Recruiting NCT05572346 - Digital App for Telerehabilitation in Respiratory Diseases
Recruiting NCT06316843 - Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 Phase 2
Completed NCT06108297 - Lithium Long COVID Dose-finding Study Phase 1